Results 121 to 127 of about 8,517,970 (127)

Safety Study on Adverse Events of Zanubrutinib Based on WHO-VigiAccess and FAERS Databases

Expert Opinion on Drug Safety
The study endeavors to elucidate AE signals associated with zanubrutinib data from the WHO-VigiAccess and FAERS databases. The aim is to furnish robust scientific evidence to inform clinical practice and regulatory decisions.We meticulously extracted all AE breports tied to zanubrutinib from the both databases, encompassing the period from the drug's ...
Qiaofang, Liang, Xiaolin, Liao, Yushen, Huang, Jiang, Zeng, Cong, Liang, Ying, He, Hongwen, Wu   +6 more
exaly   +3 more sources

Descriptive Analysis of Adverse Drug Events of Three mTOR Inhibitors Using WHO-VigiAccess

Current Drug Safety
Introduction: The mechanistic target of rapamycin (mTOR) pathway regulates cell growth, metabolism, and survival. Its dysregulation contributes to cancer, autoimmune disorders, neurodegeneration, and aging. While mTOR inhibitors such as Sirolimus, Everolimus, and Temsirolimus are therapeutically valuable, they ...
Prerna Bhati, Prakash Haloi, Havagiray R. Chitme   +2 more
openaire   +1 more source

Characterization of Adverse Drug Effects to Three Radiopharmaceuticals: A Descriptive Analysis from WHO-VigiAccess

Cancer Biotherapy and Radiopharmaceuticals
Background: Radiopharmaceuticals are being used more frequently to treat neuroendocrine tumors and advanced prostate cancer; however, their clinical application is associated with adverse drug reactions (ADRs) that may affect patient safety.
Yiheng Jin, Kunlun Gui, Kaixin Chen, Xiaowu Wang, Xinlong Wan, Shugen Qu   +5 more
openaire   +1 more source

Class-level differences and within-class heterogeneity in heart failure reporting with immune checkpoint inhibitors: a WHO vigiaccess pharmacovigilance study

European Journal of Heart Failure
Abstract Background/Introduction Immune checkpoint inhibitors (ICIs) have revolutionised cancer care, but immune-related cardiotoxicity remains poorly catalogued beyond fulminant myocarditis. Emerging case series describe a clinically silent, acute left ventricular decompensation phenotype that
Y Shhab, B Yilmaz, A Nana, I E Tarabasanu-Mihaila, Z A Stepanov, A Qsous, R Alhaddadin   +6 more
openaire   +1 more source

EPH74 COMPARATIVE POST-MARKETING SAFETY STUDY OF NIRSEVIMAB AND PALIVIZUMAB: A PHARMACOVIGILANCE ANALYSIS USING FAERS AND WHO VIGIACCESS

Value in Health
nipa chowdhury, Mohammad Al-Mamun
openaire   +1 more source

Gastrointestinal Adverse Events Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the EudraVigilance and VigiAccess Databases

Expert Opinion on Drug Safety
Mandeep Kumar Arora, Shrestha Sharma, Mohamed El-Tanani   +2 more
exaly  

Real-World Study of Adverse Events Associated With Gepant Use in Migraine Treatment Based on the VigiAccess and U.S. Food and Drug Administration’s Adverse Event Reporting System Databases

Frontiers in Pharmacology
exaly